
Summary:
In this podcast, from the 2023 DPHARM conference, a panel of experts discuss how to weigh the cost of DCTs and hybrid trials, versus the benefit that they bring to sites, patients and sponsors.
More specifically, they cover:
- What are the metrics to measure success?
- Metrics to determine costs savings of DCTs and Hybrid model versus Traditional Models – Weighing upfront costs versus potential savings in a compressed trial cycle time
- What is the impact on trial acceleration timelines? What is the impact on overall trial timelines?
- What are metrics on patient utilization of technologies saying about how well we are doing at reducing patient burden and driving more enrollment for all patients?
For more information, visit DPHARMconference.com.
Related Podcasts
View All
Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach, from DPHARM 2024 Archives

Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges

Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II
